front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |review

Caveats Neutralizing antibodies prevent repeat applications Extensive integration of viral DNA in epithelial cells of the stomach and small intestine could potentially be dangerous in case of random integration with disruption of functional genes These caveats make it rather unlikely that AAV-mediated gene therapy will be widely used for treating lactose intolerance